CNR1 and metabolic dysfunction-associated steatotic liver disease: Activation of the endocannabinoid/CB1R system inhibits fatty acid β‐oxidation in the liver (Osei‐Hyiaman et al, 2008), interrupts hepatic carbohydrate and cholesterol metabolism (Jourdan et al, 2012), and contributes to diet‐induced obesity and NAFLD.